Zim Laboratories Ltd.

₹70.16

-0.1 (-0.1%)

ZIMLAB Share Price

Pharmaceuticals & Biotechnology

As on January 27, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 341 Cr

P/E Ratio28.1

Dividend YieldN/A

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	71.61	Bearish
10-DMA	74.11	Bearish
20-DMA	72.03	Bearish
50-DMA	71.98	Bearish
100-DMA	72.42	Bearish
200-DMA	84.16	Bearish

Historical Performance

1 Year

-28.7%

3 Years

-15.7%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	3,790	3,674	3,985	3,334	3,073
Total Expenditure	3,353	3,261	3,465	2,924	2,675
Other Income	58	52	64	44	23
Operating Profit	495	465	584	454	421
Interest	114	69	56	83	109
Depreciation	201	160	175	160	158
Profit Before Tax	180	236	354	210	102
Consolidated Net Profit	122	172	244	146	73
Adjusted EPS	2	4	5	3	2

Compounded Sales Growth

10 Years:7.3

5 Years:6.4

3 Years:2.6

TTM:0.6

Compounded Profit Growth

10 Years:-27.9

5 Years:29.8

3 Years:-3.5

TTM:-6.7

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:-5.5

TTM:-28.6

Return on Equity

10 Years:1.1

5 Years:1.5

3 Years:5

last year:2.5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	487	487	487	162	162
Total Reserves	2,022	1,900	1,516	1,595	1,445
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	534	487	304	200	194
Other Current Liabilities	408	412	291	447	312
Short Term Borrowings	525	550	229	173	446
Total Liabilities	4,720	4,468	3,416	3,431	3,222
Capital Work in Progress	441	235	178	51	46
Long Term Loans & Advances	52	157	144	118	113
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	323	335	319	424	553
Total Current Assets	2,313	2,276	1,909	2,136	1,918
Total Assets	4,720	4,468	3,416	3,431	3,222
Adjusted Book Value	51	49	41	36	33

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 28.1, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -4.9%, indicating poor shareholder returns.
The stock carries a beta of 0.8, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹495 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹3790 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 714024

No. of Shares: 10177 (Approx)

Performance:-28.6%

P/L: ₹-285976

NIFTY Performance: 9.7%

1 day Top Gainers